SuperworthPacira BioSciences EPS PCRX
Diluted earnings per share by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jun 30, 2026
- $0.35
- Latest quarter, Q2 FY26
- $0.12
- Fiscal year 2025
- $0.15
Pacira BioSciences' earnings per share was $0.35 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was $0.12.
Over the five fiscal years to FY2025 it shrank 46% a year on average.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $0.15 | n/a |
| FY2024 | −$2.18 | −425% |
| FY2023 | $0.67 | +116% |
| FY2022 | $0.31 | −66% |
| FY2021 | $0.92 | −72% |
| FY2020 | $3.28 | n/a |
| FY2019 | −$0.28 | n/a |
| FY2018 | −$0.02 | n/a |
| FY2017 | −$1.09 | n/a |
| FY2016 | −$1.01 | −2625% |
| FY2015 | $0.04 | n/a |
| FY2014 | −$0.95 | n/a |
| FY2013 | −$1.93 | n/a |
| FY2012 | −$1.73 | n/a |
| FY2011 | −$2.76 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $0.12 | n/a | $0.35 | |
| Q1 FY26 | $0.07 | −30% | $0.12 | |
| Q4 FY25 | $0.04 | −89% | $0.15 | |
| Q3 FY25 | $0.12 | n/a | $0.46 | |
| Q2 FY25 | −$0.11 | −128% | −$2.77 | |
| Q1 FY25 | $0.10 | −47% | −$2.27 | |
| Q4 FY24 | $0.35 | −3% | −$2.18 | |
| Q3 FY24 | −$3.11 | −1452% | −$2.17 | |
| Q2 FY24 | $0.39 | −24% | $1.17 | |
| Q1 FY24 | $0.19 | n/a | $1.29 | |
| Q4 FY23 | $0.36 | n/a | $0.67 | |
| Q3 FY23 | $0.23 | n/a | $0.09 |
Against its peers
Companies in Drug Manufacturers - General nearest Pacira BioSciences' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| PCRXPacira BioSciences | $0.35 | |
| ANABAnaptysbio | $4.57 | |
| PAHCPhibro Animal Health | $2.44 | +107% a year |
| ANIPANI Pharmaceuticals | $4.70 | |
| OMEROmeros | $1.52 | |
| AMPHAmphastar Pharmaceuticals | $1.70 | −36% a year |
| HRMYHarmony Biosciences | $3.09 | −0% a year |
| PBHPrestige Consumer Healthcare | $3.57 | −16% a year |
| ABUSArbutus Biopharma | $0.78 | |
| NRIXNurix Therapeutics | $2.31 | |
| COLLCollegium Pharmaceutical | $1.24 | +19% a year |
| Peer median | $2.38 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Pacira BioSciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.